Trademark: 97503170
Status Date
Thursday, December 14, 2023
Filing Date
Thursday, July 14, 2022
Published for Opposition
Tuesday, May 2, 2023
5 Medical therapeutic preparations, namely, antisense therapeutics; therapeutics in the nature of pharmaceuticals for treatment of Duchenne Muscular Dystrophy (DMD)
42 research and development of gene therapeutics, namely, antisense therapeutics; research and development of anti-miRNA technology for the treatment of Duchenne Muscular Dystrophy (DMD); research and development of therapeutics for treatment of Duchenne Muscular Dystrophy (DMD); pharmaceutical and therapeutic research and development
The mark consists of a stylized helix shaped design forming the letter "e".
ELENAE
Color is not claimed as a feature of the mark.
Mar 27, 2023
Examiners Amendment -Written
Jul 18, 2022
New Application Entered
Aug 3, 2022
New Application Office Supplied Data Entered
Aug 4, 2022
Notice Of Design Search Code E-Mailed
Mar 23, 2023
Assigned To Examiner
Mar 27, 2023
Examiners Amendment E-Mailed
Mar 27, 2023
Notification Of Examiners Amendment E-Mailed
Mar 27, 2023
Examiner's Amendment Entered
Mar 27, 2023
Approved For Pub - Principal Register
Apr 12, 2023
Notification Of Notice Of Publication E-Mailed
May 2, 2023
Published For Opposition
May 2, 2023
Official Gazette Publication Confirmation E-Mailed
Dec 14, 2023
Sou Teas Extension Received
Dec 14, 2023
Sou Extension 1 Filed
Dec 14, 2023
Sou Extension 1 Granted
Apr 23, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 23, 2024
Teas Change Of Correspondence Received
Apr 23, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 27, 2023
Noa E-Mailed - Sou Required From Applicant
Dec 16, 2023
Notice Of Approval Of Extension Request E-Mailed
Trademark Alertz updated from USPTO on 2030-01-24
